EvaluatePharma - Johnson & Johnson - Worldwide

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile



Profile	Johnson & Johnson (JNJ) is a New Jersey based global healthcare pharmaceutical & medical device company focused on consumer health, diagnostics, biologics & pharmaceuticals.
Listed or Private Company	Listed
Company Classification	Global Majors; Med Tech
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event


Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
7/21/2010	21 Jul: FDA reports problems with the company's test procedures, record-keeping and handling of consumer complaints at a manufacturing plant in Lancaster. 21 Jul: UBS maintains its "buy" rating but lowers price target to $69 from $75, after the company reduces its 2010 profit guidance on 20 Jul. 20 Jul: Company's Q2 results miss expectations and company lowers its 2010 profit forecast by $0.15 per share, citing repeated recalls as well as pricing pressures on its drugs in Europe. Standard & Poor's downgrades rating to "hold" from "buy".	157,541	-2.5%	-4,027

Top 3 Products (Worldwide Sales 2007/08)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2007	2008	2008
1	Remicade	infliximab	Other anti-rheumatics	2,534²	2,810³	+11%
2	Topamax	topiramate	Anti-epileptics	2,453⁴	2,731⁵	+11%
3	Procrit/Eprex	epoetin alfa	Anti-anaemics	2,885⁶	2,460⁷	-15%

Note: Shaded Cells⁸

RX Sales Chart

Johnson & Johnson	Data		Growth
	2007	2008	2008
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals⁹	23,930¹⁰	23,509¹¹	-2%

Therapy Area Focus in 2008

Johnson & Johnson
	2008
WW Rx & OTC Sales By Therapy Area
Main Categories
Blood	2,501
Cardiovascular	58
Central Nervous System	11,380
Dermatology	331
Gastro-Intestinal	1,414
Genito-Urinary	942
Musculoskeletal	2,973
Oncology & Immunomodulators	1,056
Respiratory	193
Sensory Organs	3
Systemic Anti-Infectives	2,439
Other Rx & OTC Pharma	2,380

EvaluatePharma® Coverage of Marketed and Pipeline Products


	Product Count
Johnson & Johnson ¹²	439

2009 Product Sales analysis
2009 Pharmaceutical Sales
2009 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases


EP Vantage - last 6 months

Event - Pradaxa adcom set for wide scrutiny (September 02, 2010)

ESC - Blood thinners generate strong data (August 31, 2010)

Preview - ESC likely to be dominated by oral blood thinners (August 26, 2010)

Preview - ESC to throw up more than just the hot topics (August 26, 2010)

Event - Basilea hoping for Christmas bonus (August 24, 2010)

Displaying 5 out of a possible 31 unique stories.
Results Sorted By date
Display All Stories

Ranked on:
Annual Sales WW
2008

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):

X) +XXXX XX (+X.X%).

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):
X) +XXX XXXX (+XX.X%).
X) +XXXX XX (+XX.X%).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXXX (XXXXXXXXXX), X XXXXXXXX XXXXXXXX XXX XXX XXXXXXXXX XX XXXXX’X XXXXXXX, XXXXXXXXXX XXXXXXXXXXX, XXXXXXXXX, XXXXXXXXX XXXXXXXXX, XXXXXXXXXX XXXXXXX XXX XXX XX XXX XXXXXXXXX XX XXXXXXXXXX XXXXXXXXX, XXXXXXXX XXXXX XX $X.X XXXXXXX XX XXXX, XXXX XXXXXX XX XX.X% XXXX XXXXX XXXX. XXXXXX XXX XXXXXX XX XXXXXXXXX XXXXXX XXX XX XXXXXXXX XXXXXXXXXXX XXX XXXXXXX XXXXXX XXXXXX. XXXXXX XXXX, XXXXXXXX XXXXXXXX XXXXXXXX XXXX XXX XXXXXXXX XXXXXXXXXX XXX XXXXXXXXX XXXXX’X XXXXXXX XXXXXXXXXXX. XXXXXXXX XX XXXXXXXXX XX X XXXXXX XXXXX XX XXXXXXXXXXXX XXXXXXXXX XXXXXXXXXXX XXX XX XXX XXXXXXXX XXX XXX XXXXXXXXX XX XXXXXXXXXXX XXX XXXXXXXX XXXXXXXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXX XXXXXX XXXXXXXX XXX XXXXXX XXXXXXXXXXX XX...XXXXXXXX, X XXXXXXXX XXXXXXXX XXX XXX XXXXXXXXX XX X XXXXXX XX XXXXXX XXXXXXXX XXXXXXXXXXXX XXXXXXXX.

XXXXXX: XXXXXXXX-XXXXXX XXXX XX-X, XXXX X:
XXXXXXXX XX XXXXXXXX XXXX XXX XXXXXXXXXXXX XX XXXXXXXX, XXX., X XXXXXXX & XXXXXXX XXXXXXX. XXXXXX XXXX, XXXXXXXX-XXXXXX XXXXXXXXX XX XXXXXX XXXXX XXX XXXXXXXX XXXX XXXXXXXX XXX XXXXXXX XXXXXX XX XXXXXXX XXX XXXXXXXXXXXXX XXXXXXXXX, X XXXXX XXXXX XXXXXXXXXX XXXXXXXX XXXXXXXXX XX XXXXX XXX XXXXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXX XXXXXXXXX XXXXXX XX XXXX XXXXXXXX XXXXXXX XX XXX X.X., XXXXX XXX XXXXXXX XXXXX XXXXXXX. XX XXXXXXXX XXXX, XXXXXXXX-XXXXXX XXX XXXXXXXX XXXXXXX XXXXX XXXXXXXXXXXX XXXXXXXXX XXXXXXXXX XXX XXXXXXXXXXX, XXXXXXXXXXXXXXXXX XXX XXXXXXXXXXXX XX XXXX XXXXXXXX XXX XXXXXXXXX, XXXXXXXXX XXXXXXXX-XXXXXX’X XXXXXX XX XXXXXXXXXXX XXXXXX XXXXXXXX XX XXXXX XXX XXXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXXXXX XXXXXX XXX XXXXXXXXX. XXXXXXXXX XXXX XXXXXXXXXX XXXXXXXX XX XXXXXXXXX XX XXX XX, XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXX XXX XXXX XXXXXXXX XXXX XXX XXXXXX XXX XX XXXXX XXXXX XXX XXXXX XXXXXXXXXX XXXX XX XXXXXXXXX XXXXXX XXX XX. XXXXXXXX XXXX XXXXXXX X XXXXXXXXXXXXX XXXXXXXXX XXXXX XX XXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXXXXX XX XXXX XXXXXXXX XX XXX XXXXXXXX-XXXXXX XXXXXXXXX XXXXXXXXX XXXXXXX XXXX XXX XXXX, XXX XXX XXXXX XX XXXXXXX XXXX XXXXXX XXXXX XXXXXXXXXX XXX XXX XXXXXXXXX XX XXX XXXX. XXX XXXXXXX XX XXX XXXXXXXX XX XXXXXXXX XXXXXXXXX XXXXXX XXX XXX XXXXXX XXXXXXX XXXXXXXXXXX XXX XXX XXXXXXXX XXX XXX XXXXXXXXXXX XX XXXXXXXX XX XXXXXXXXX XXXXX XXXXXXX XXXXX XX XXXXXXXXX X, XXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXXXXXX XXXXXXX XXX XXXXXX XXXXXXXXX XXX X XXXXX’X XXXXXXX XXXXXXXXXX XX XXX XXXXXXXXXXX, XXXX XX XXXXXX XXX XXXXXXXX XX XXXXXXXXXXX.

XXXX XX:
XXXXXXXX XX XXXXXXXXXX XXX XXX XXXXXXXXX XX XXXXXXXXXXXX XXXXXXXX XXXX XX XXXXXXXXXX XXXXXXXXX, XXXXX XXXXXXXXXX XXXXXXXXX, XXXXXXXXX XXXXXXXXX, XXXXX’X XXXXXXX, XXXXXXXXXX XXXXXXXXXXX, XXXXXX XXXXXXXXX XXX XXXXXXXXXX XXXXXXX. XXXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXX XXXXXXX XXXXXXXX XXXXXXXXXXXXXX XXXXXXX XXXX (XXXXX XXX XXXXXXXXXXX XXXXXXXXX). XXXXXXXX XX XXXXXXXX XXXX XXX XXXXXXXXXXXX XX XXXXXXXX, XXX., X XXXXXXX & XXXXXXX XXXXXXX. XXXXXX XXXX, XXXXXXXX-XXXXXX XXXXXXXXX XX XXXXXX XXXXX XXX XXXXXXXX XXXX XXXXXXXX XXX XXXXXXX XXXXXX XX XXXXXXX XXX XXXXXXXXXXXXX XXXXXXXXX, X XXXXX XXXXX XXXXXXXXXX XXXXXXXX XXXXXXXXX XX XXXXX XXX XXXXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXX XXXXXXXXX XXXXXX XX XXXX XXXXXXXX XXXXXXX XX XXX X.X., XXXXX XXX XXXXXXX XXXXX XXXXXXX. XX XXXXXXXX XXXX, XXXXXXXX-XXXXXX XXX XXXXXXXX XXXXXXX XXXXX XXXXXXXXXXXX XXXXXXXXX XXXXXXXXX XXX XXXXXXXXXXX, XXXXXXXXXXXXXXXXX XXX XXXXXXXXXXXX XX XXXX XXXXXXXX XXX XXXXXXXXX, XXXXXXXXX XXXXXXXX-XXXXXX’X XXXXXX XX XXXXXXXXXXX XXXXXX XXXXXXXX XX XXXXX XXX XXXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXXXXX XXXXXX XXX XXXXXXXXX. XXXXXXXXX XXXX XXXXXXXXXX XXXXXXXX XX XXXXXXXXX XX XXX XX, XXXXXXXX-XXXXXX’X XXXXXXXXX XXXXXX XXX XXXX XXXXXXXX XXXX XXX XXXXXX XXX XX XXXXX XXXXX XXX XXXXX XXXXXXXXXX XXXX XX XXXXXXXXX XXXXXX XXX XX. XXXXXXXX XXXX XXXXXXX X XXXXXXXXXXXXX XXXXXXXXX XXXXX XX XXXXXXX XX XXXXXXXX-XXXXXX’X XXXXXXXXXXXX XX XXXX XXXXXXXX XX XXX XXXXXXXX-XXXXXX XXXXXXXXX XXXXXXXXX XXXXXXX XXXX XXX XXXX, XXX XXX XXXXX XX XXXXXXX XXXX XXXXXX XXXXX XXXXXXXXXX XXX XXX XXXXXXXXX XX XXX XXXX. XXX XXXXXXX XX XXX XXXXXXXX XX XXXXXXXX XXXXXXXXX XXXXXX XXX XXX XXXXXX XXXXXXX XXXXXXXXXXX XXX XXX XXXXXXXX XXX XXX XXXXXXXXXXX XX XXXXXXXX XX XXXXXXXXX XXXXX XXXXXXX XXXXX XX XXXXXXXXX X, XXXX. XXXXXXXX-XXXXXX XXX XXXXXXXXXXXXX XXXXXXX XXX XXXXXX XXXXXXXXX XXX X XXXXX’X XXXXXXX XXXXXXXXXX XX XXX XXXXXXXXXXX, XXXX XX XXXXXX XXX XXXXXXXX XX XXXXXXXXXXX. XX XXXXXXXX, XXXXXXXX-XXXXXX XXX XXXXXXXX XXXXXX XX XXXXXXX XX XXXXXXXXXXXX XXXXXX XX XXX XXXXXXXXXXXXXXXXX XX XXXXXXXXX XXX XXXXXXX XXXXXX XX XXXXX XXX XXXXXXXXXXX XXXXX. XXX XXX XXXXXX XX XXXX XXXXXX, XXXXXXXX-XXXXXX XXXX XX XXXXXXX XXXXXXX XX $XX XXXXXXX, XXXXX XX XXXXXXXX XX XXXXXXXX XXX XXXXXXXXXXX XXXXXXXX XXX XXX XXXX XXXXX XXXXXXXX XX, XXXX.

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):

X) +XXXX XX (+XX.X%).

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):
X) +XXX XXXXXX (+XX.X%)
X) +XX XXXX (+XXX.X%).
X) +XXXX XX (+XX.X%).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXXX (XXXXXXXXXX), X XXXXXXXX XXXXXXXX XXX XXX XXXXXXXXX XX XXXXX’X XXXXXXX, XXXXXXXXXX XXXXXXXXXXX, XXXXXXXXX, XXXXXXXXX XXXXXXXXX, XXXXXXXXXX XXXXXXX XXX XXX XX XXX XXXXXXXXX XX XXXXXXXXXX XXXXXXXXX, XXXXXXXX XXXXX XX $X.X XXXXXXX XX XXXX, XXXX XXXXXX XX XX.X% XXXX XXXXX XXXX. XXXXXX XXX XXXXXX XX XXXXXXXXX XXXXXX XXX XX XXX XXXXXXXXXXXX XX XXX XXXXXXXX XXXX XXX XXXXXXX XXXXXX XXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXX XXXXXXX XXXXXXX XXX XXXXXX XXXXXXXXXXX XX …XXXXXXXX, X XXXXXXXX XXXXXXXX XXX XXX XXXXXXXXX XX X XXXXXX XX XXXXXX XXXXXXXX XXXXXXXXXXXX XXXXXXXX;…

XXXXXX: XXXX XX-X, XXXX XX:
XX XXX XXXX, XXXXXXXX, XXX. (XXX XXXX) XXXXX X XXXXXXX XXXXXXX XXXXXXXXX, XXX. (XXXXXXXXX) XX X.X. XXXXXXXX XXXXX XXX XXX XXXXXXX XXXXXXXX XX XXXXXXXXXX XXXXXXX XX XXXXXXXXXX XXX XXXXXXX XX XXXXXX. XXXXX XX XXXXXX XXXX, XXXXXXXX XXX X XXXXXXXXXX XXXXX XXXX XXXXXX XXXX XXXXXXXX (XXX XXX XXXXXXXX XX XXXXXXXXX) XXX XXXXXXXX ® XXX XXX XXXX XXXXXX XXXXXXXXX XX XXXXXXXX. XXXXXXXX XXX XXXXXXXXXX XXXX XXXXXXXXXX XXX XXXXXXX XXXXXX XXXXXXXXX. XXXXXXXXX XXX XXXXX X XXXXXXXXXXXX XXXXXXXX XXXX XXXXXXXX XXXXXXXXX XXX XXXXXXX XX XXXXXXX XXX XXXX XXX XXXXXXXXXXX XX XXXXXXXX ® , XXXXXXXXXXX, XXXXXXXXX XXX XXXXXX XXXXXXXX XXXXXXX XX XXX XXXXXXX XXXXXXXX XX XXX XXXXXXXXXXXX XX XXXXXXXXXX XXXX XXXXXXX XXXXXXXXXXX XXX XXXXXXXXXX.

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):

X) +XXXX XX (+XX.X%).
X) +XXX XXXX (X.X%).
X) +XXXX XX (+XX.X%).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXX (XXXXXXXXXX), XXXXX XXX XXXX XXXXXXXX XXX XXXXXXXXXX XXX XXXXXXXXXXX XXX XX XXXXXXXX, XX XXXX XX XXX XXX XXXXXXXXXXXX XXXXXXXXX XX XXXXXXXXX, XXXXXXXX $X.X XXXXXXX XX XXXXX XX XXXX, XX XXXXXXXX XX XX.X% XXXX XXXXX XXXX. XXX XXXXX XXXXXXXXXXX XX XXX XXXXXX XXX XXX XXXXXXXXX XXXXXXX XX XXX XXXXXXXX XXXXXXXX. XXX XXXXXX XXX XXXXXXX (XXXXXXXXXX) XX XXX X.X. XXXX XXXXXX XX XXXXXXXXX XXXX. XXX XXXXXXX XX XX XXXXXX XX XXXX XXX XXX XXXXXXXXX XXXXXXXXX XXXX XXX XXX, XXXXX XX XXXXXXXX, XXXXX XXXXX XXXXXX XXXXXXXXXXX XX XXX X.X. XXXXX XXXXX XXXX. XX XXXX, X.X. XXXXX XX XXXXXXX XXXX $X.X XXXXXXX. XXX XXXXXXXXXX XX X XXXXXXX XXXXXX XX XXXX XX XXXXXX XXXXXXXXXXX XX XXXXXX XX XXXXXX XX X XXXXXXXXXXX XXXXXXXXX XX XXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXX XXXXXX XXXXXXXX XXX XXXXXX XXXXXXXXXXX XX...XXXXXXX, XX XXXXXXXXXXXXX XXX X XXXXXXXXX XXX XXX XXXXXXXXXX XX XXXXXXXX XXXXXXXXX.

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):

X) +XXXX XX (+XX.X%).
X) +XXX XXXX (X.X%).
X) +XXXX XX (+XX.X%).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXX (XXXXXXXXXX), XXXXX XXX XXXX XXXXXXXX XXX XXXXXXXXXX XXX XXXXXXXXXXX XXX XX XXXXXXXX, XX XXXX XX XXX XXX XXXXXXXXXXXX XXXXXXXXX XX XXXXXXXXX, XXXXXXXX XXXXX XX $X.X XXXXXXX XX XXXX, XX XXXXXXXX XX XX.X% XXXX XXXXX XXXX. XXX XXXXXX XXX XXXXXXXXX XXX XX XXXXXXXXX XX XXX XXXXXXXX XXXXXXXX XXXXXXXXX XXXXXX XX XXXXXXX XXXXXXXXXXX XX XXXXXXX XXXXXXX XXXXXXX XXX X.X. XXX XXXXXX XXX XXXXXXX (XXXXXXXXXX) XX XXX X.X. XXXXXXX XX XXXXXXXXX XXXX. XX XXXX XXXX, XXX X.X. XXXX XXX XXXX XXXXXXXXXXXXXX (XXX) XXXXXXX XXXXXXXXX XXXXXXXXXXX XXX XXXXXXX, XXXXX XXXXXXX XXXXXX XXXXXXXXXXX XX XXX X.X. XXXXX XXXXX XXXX. XX XXXX, X.X. XXXXX XX XXXXXXX XXXX $X.X XXXXXXX. XXX XXXXXXXXXX XX XXX XXXXXXX XXXXXX XX XXXX XX XXXXXX XXXXXXXXXXX XX XXXXXX XX XXXXXX XX X XXXXXXXXXXX XXXXXXXXX XX XXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXX XXXXXXX XXXXXXX XXX XXXXXX XXXXXXXXXXX XX…. XXXXXXX, XX XXXXXXXXXXXXX XXX X XXXXXXXXX XXX XXX XXXXXXXXXX XX XXXXXXXX XXXXXXXXX.

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):

XXXXX/XXXXXXX
X) +XXXX XX (-XX.X%).
X) +XXXX XXXX (-X.X%).
X) +XXXX XX (-XX.X%).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXX (XXXXXXX XXXX) XXX XXXXX (XXXXXXX XXXX) XXX XXXXXXXX XXXXX XX $X.X XXXXXXX XX XXXX, X XXXXXXX XX X.X% XXXXXXXX XX XXXXX XXXX. XXX XXXXXXX XXX XXXXXXXXX XXX XX XXX XXXXXXXXX XXXXXXX XXX XXXXXXXXXXXXXX XXXXXXXXXXX XXXXXX (XXXX). XXXXXXX XX XXX XXXX XXX XXXXXXX XXX XXXXXXXX XXX XXXXXXXX XXXXXX X XXXXXXXX XXXXXXXX XXXXXXXXXXXXX, XXXXX XXXXXXXXXXXXX XXXXXX XXX XXXXXXXXXXXXX XX XXXX XX XXXXXXXX XX XXX X.X. XXXXXXX XXXX XXXXXXXX XX XXX X.X. XXXX XXXXXXX XX X XXXXX XXXXXX, XXXXX XXX XXXXXXXXXX XXXXXX XXXXXX XXXXX. XXX XXXXX XXX XXXXXXX XXXX XXXXXXXX XX XXXX XXXXX XXXXXX XX XXXXXXXXXXXXX XXXXXXX XXX X.X.
XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXX XXX XXXXXXXXXX XXXXXXXX XX XXXXX XXXXX XX XXXXXXX, X XXXXXXX XXX XXX XXXXXXXXX XX XXXXXX, XXX XX X XXXXXXX XX XXX XXXXXX. XXXX XXXXXX XXXXXXX XX XXXXXXX XX XXXXXXXX XXXXXXX XXXX XXXXXX XXX XXXX XXX X XXXXXXXX XXXXXXXXXX XXXXXX XX XXX XXXXXXX XXX XXXXXXXX & XXXXXXXX XXXXXXXX XXXXX XXX XXXXXXXX XXXXXXXX XXXXXXXX XXXXXXX.

XXXXXXXX XX $X (% XXXXXXXXXXX XXXXXX, XXXX. XXXXXXXX):

XXXXX/XXXXXXX
X) +XXXX XX (-XX.X%).
X) +XXXX XXXX (-XX.X%).
X) +XXXX XX (-XX.X%).

XXXXXXX XXXXXXX:

XXXXXX: XXXX XX-X, XXXX XX:
XXXXXXX (XXXXXXX XXXX) XXX XXXXX (XXXXXXX XXXX) XXX XXXXXXXX XXXXX XX $X.X XXXXXXX XX XXXX, X XXXXXXX XX XX.X% XXXXXXXX XX XXXXX XXXX. XXX XXXXXXX XXX XXXXXXXXX XXX XX XXX XXXXXXXXX XXXXXXX XXX XXXXXXXXXXXXXX XXXXXXXXXXX XXXXXX (XXXX) XX XXX X.X. XXX XXX XXXXXX XX XXXXX XXXXXXXXX X XXXXXXXX XXXXXXXXXX XXXXXX XXXXXXXX XXXXXXXXX XX XXX XXXXX XXX XXXX, XXXXXXXXX XXXXXXX. XXX XXXXX XXX XXXXXXX XXX XXXXXXX XXXX XX, XXXX, XXXXX XX XXXXXX XX XXXXXXXX XXXXXX XXXX XXX XXX XXX XX XXXX XX XXXXXXXX XXXX XXXXXX. XXXXXXX XXX X.X., XXX XXXXXXXXXXX XXX XXX XXXXXXXX XXXXXX XXXX XXXXXX XXXX XXXXXXXXXXX XX XXX XXXXX XXXXX XXXXXXX XXX XXXXX. XXXXXXXXXXX XXXX XXXXXXXX XXXXXXXXXX XXXXXXXXX XXXXXXX XX XXX XXXXX XXX XXXX, XXXXXXXXX XXXXX, XXX XXXXXXX XXXXXXXXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
….XXXXX XX XXXXXXX, X XXXXXXX XXX XXX XXXXXXXXX XX XXXXXX, XXXX XXXXX XXX XX X XXXXXXX XX XXX XXXXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

Company Specific NamePharmaceuticals

XXXXXXXX XX $X:
XXXXX XXXXXXXXXXXXXXX XXXX:
X) XXXXXXXX XX XX XXX XXXXXX XXXXX.
X) XXXXXX XXX XX-XXXXXXXXX XXXXXXX.

XXXXXXXX XX $X:
X) +XX,XXX XXXXX XXXXXXXXXXXXXXX

XXXX:
X) XXXXXXXX XX XX XXX XXXXXX XXXXX.
X) XXXXXX XXX XX-XXXXXXXXX XXXXXXX.